Targeting PI3K Signaling in Combination Cancer Therapy

被引：126

作者：

Pons-Tostivint, Elvire ^{[1
,2
]}

Thibault, Benoit ^{[1
,2
]}

Guillermet-Guibert, Julie ^{[1
,2
]}

机构：

[1] Univ Toulouse III Paul Sabatier, CRCT, INSERM, Toulouse, France

[2] Lab Excellence LABEX TouCAN, Toulouse, France

来源：

TRENDS IN CANCER | 2017年 / 3卷 / 06期

关键词：

METASTATIC BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; PANCREATIC-CELL PLASTICITY; 1ST-IN-HUMAN PHASE-I; BUPARLISIB BKM120; PIK3CA MUTATIONS; DOSE-ESCALATION; WILD-TYPE; TRASTUZUMAB RESISTANCE; PILARALISIB SAR245408;

D O I：

10.1016/j.trecan.2017.04.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway appears to be a promising therapy in solid cancers; however, first early clinical trials with PI3K inhibitors in monotherapy have been disappointing. A massive array of preclinical and clinical trials are currently evaluating combinations of PI3K inhibitors in targeted therapies. These combinations include co-treatments with drugs directed against other intra-/extracellular signaling molecules, nuclear hormone receptors, DNA damage repair enzymes, and immune modulators. We review the literature and pinpoint mechanisms of action in different genomic and organ contexts. Combinatorial approaches are potentially superior to monotherapies and should become alternative clinical strategies to treat cancer patients.

引用

页码：454 / 469

页数：16

共 111 条

[1] The Molecular Taxonomy of Primary Prostate Cancer [J].

Abeshouse, Adam ;

Ahn, Jaeil ;

Akbani, Rehan ;

Ally, Adrian ;

Amin, Samirkumar ;

Andry, Christopher D. ;

Annala, Matti ;

Aprikian, Armen ;

Armenia, Joshua ;

Arora, Arshi ;

Auman, J. Todd ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barbieri, Christopher E. ;

Bauer, Thomas ;

Benz, Christopher C. ;

Bergeron, Alain ;

Beroukhim, Rameen ;

Berrios, Mario ;

Bivol, Adrian ;

Bodenheimer, Tom ;

Boice, Lori ;

Bootwalla, Moiz S. ;

dos Reis, Rodolfo Borges ;

Boutros, Paul C. ;

Bowen, Jay ;

Bowlby, Reanne ;

Boyd, Jeffrey ;

Bradley, Robert K. ;

Breggia, Anne ;

Brimo, Fadi ;

Bristow, Christopher A. ;

Brooks, Denise ;

Broom, Bradley M. ;

Bryce, Alan H. ;

Bubley, Glenn ;

Burks, Eric ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Canes, David ;

Carlotti, Carlos G. ;

Carlsen, Rebecca ;

Carmel, Michel ;

Carroll, Peter R. ;

Carter, Scott L. ;

Cartun, Richard ;

Carver, Brett S. ;

Chan, June M. ;

Chang, Matthew T. ;

Chen, Yu .

CELL, 2015, 163 (04) :1011-1025

[2] Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer [J].

Alagesan, Brinda ;

Contino, Gianmarco ;

Guimaraes, Alexander R. ;

Corcoran, Ryan B. ;

Deshpande, Vikram ;

Wojtkiewicz, Gregory R. ;

Hezel, Aram F. ;

Wong, Kwok-Kin ;

Loda, Massimo ;

Weissleder, Ralph ;

Benes, Cyril ;

Engelman, Jeffrey A. ;

Bardeesy, Nabeel .

CLINICAL CANCER RESEARCH, 2015, 21 (02) :396-404

[3] Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[4] Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer [J].

Baer, R. ;

Pyronnet, S. ;

Guillermet-Guibert, J. .

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (04) :320-321

[5] Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α [J].

Baer, Romain ;

Cintas, Celia ;

Dufresne, Marlene ;

Cassant-Sourdy, Stephanie ;

Schoenhuber, Nina ;

Planque, Laetitia ;

Lulka, Hubert ;

Couderc, Bettina ;

Bousquet, Corinne ;

Garmy-Susini, Barbara ;

Vanhaesebroeck, Bart ;

Pyronnet, Stephane ;

Saur, Dieter ;

Guillermet-Guibert, Julie .

GENES & DEVELOPMENT, 2014, 28 (23) :2621-2635

[6]

Baselga J., 2015, P 2015 SAN ANT BREAS

[7] Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Im, Seock-Ah ;

Clark, Emma ;

Ross, Graham ;

Kiermaier, Astrid ;

Swain, Sandra M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3753-+

[8] Targeting PI3 kinase in cancer [J].

Bauer, Todd M. ;

Patel, Manish R. ;

Infante, Jeffrey R. .

PHARMACOLOGY & THERAPEUTICS, 2015, 146 :53-60

[9] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J].

Bedard, Philippe L. ;

Tabernero, Josep ;

Janku, Filip ;

Wainberg, Zev A. ;

Paz-Ares, Luis ;

Vansteenkiste, Johan ;

Van Cutsem, Eric ;

Perez-Garcia, Jose ;

Stathis, Anastasios ;

Britten, Carolyn D. ;

Le, Ngocdiep ;

Carter, Kirsten ;

Demanse, David ;

Csonka, Denes ;

Peters, Malte ;

Zubel, Angela ;

Nauwelaerts, Heidi ;

Sessa, Cristiana .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :730-738

[10] Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor [J].

Berenjeno, Inma M. ;

Guillermet-Guibert, Julie ;

Pearce, Wayne ;

Gray, Alexander ;

Fleming, Stewart ;

Vanhaesebroeck, Bart .

BIOCHEMICAL JOURNAL, 2012, 442 :151-159

← 1 2 3 4 5 6 7 8 9 10 →